CNSX:ATT - Abattis Bioceuticals Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: C$0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
C$0.00
+0.30 (1.20%)

This chart shows the closing price for ATT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Abattis Bioceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATT

Analyst Price Target is C$0.00
This price target is based on 0 analysts offering 12 month price targets for Abattis Bioceuticals in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a NaN upside from the last price of C$0.00.

This chart shows the closing price for ATT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Abattis Bioceuticals. This rating has held steady since August 2019, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/12/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/12/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/10/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/8/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/7/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/5/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/22/2018Fundamental ResearchInitiated CoverageBuy$0.30
(Data available from 8/5/2016 forward)

Abattis Bioceuticals

Abattis Bioceuticals Corp. is a specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. It offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. It is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

1,420,000 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Abattis Bioceuticals?

The following Wall Street analysts have issued stock ratings on Abattis Bioceuticals in the last year:
View the latest analyst ratings for ATT.

What is the current price target for Abattis Bioceuticals?

0 Wall Street analysts have set twelve-month price targets for Abattis Bioceuticals in the last year. has the lowest price target set, forecasting a price of C$10,000,000.00 for Abattis Bioceuticals in the next year.
View the latest price targets for ATT.

What is the current consensus analyst rating for Abattis Bioceuticals?

Abattis Bioceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ATT.

What other companies compete with Abattis Bioceuticals?

How do I contact Abattis Bioceuticals' investor relations team?

Abattis Bioceuticals' physical mailing address is 224-970 Burrard St, VANCOUVER, BC V6Z 2R4, Canada. The company's listed phone number is +1-604-3360881. The official website for Abattis Bioceuticals is www.abattis.com.